India maps pharma value chain
- India's Department of Pharmaceuticals commissioned a consultancy to map the pharma and medical‑devices logistics value chain. - The study targets cold‑chain gaps, customs delays and cluster strengths in Gujarat and Hyderabad, according to the thread. - Industry association AiMeD is reportedly backing data‑driven reforms to reduce costs and regulatory bottlenecks in the $65B+ sector (x.com).
India’s drug-policy department has opened a new study to map how medicines and medical devices move across India, from raw materials to last-mile delivery. (financialexpress.com) The Department of Pharmaceuticals posted its request for proposals on April 17, 2026, with bids due by May 15, 2026, for a consultant to build a logistics plan for both domestic and export-import flows. (pharma-dept.gov.in) The brief says the consultant must map costs across transport, storage, handling and regulatory fees, and identify bottlenecks including cold-chain failures, customs delays and weak transport links. (financialexpress.com) The study is also supposed to profile major manufacturing clusters in Gujarat, Maharashtra, Andhra Pradesh, Kerala, Himachal Pradesh and Hyderabad, and flag the most urgent problem in each location. (financialexpress.com) India’s pharmaceutical market stood at about $55 billion in 2025, according to Bain & Company figures cited by India Brand Equity Foundation, and the same presentation projects a $120 billion to $130 billion market by 2030. (ibef.org) That scale has turned logistics into an industrial-policy issue as much as a transport problem: the Department of Pharmaceuticals says the assignment covers drugs, active pharmaceutical ingredients and medical devices across international and domestic markets. (pharmabiz.com) The government has been moving toward this for more than a year. In April 2025, the department first sought expressions of interest for a study to assess infrastructure, logistics practices, policy and regulation in the sector. (pharmabiz.com) Industry groups have been pressing for policy changes in parallel. In March 2025, the Association of Indian Medical Device Industry, or AiMeD, backed a white paper calling for reforms to strengthen domestic manufacturing and reduce import dependence in medical technology. (theweek.in) The department’s website now lists the logistics study in its “What’s New” section, which means the next step is no longer whether the mapping happens but which firm wins the job. (pharma-dept.gov.in)
